Quarterly ResultApr 28, 2026, 04:14 PM
OPK Q1 Net Loss $(54.8)M, EPS $(0.07); Repurchases $4.8M Shares
AI Summary
OPKO Health, Inc. reported a net loss of $(54.8) million, or $(0.07) per share, for Q1 2026, an improvement from a net loss of $(67.6) million, or $(0.10) per share, in Q1 2025. Total revenues decreased to $124.2 million from $149.9 million year-over-year, primarily due to the divestment of certain BioReference oncology diagnostics assets in September 2025. The company also repurchased $4.8 million of common stock during the quarter and is appealing a $246 million foreign tax assessment.
Key Highlights
- Net loss improved to $(54.8)M in Q1 2026 from $(67.6)M in Q1 2025.
- Diluted EPS improved to $(0.07) in Q1 2026 from $(0.10) in Q1 2025.
- Total revenues decreased to $124.2M in Q1 2026 from $149.9M in Q1 2025.
- Revenue from services fell to $72.2M (Q1 2026) from $102.8M (Q1 2025).
- Revenue from products increased to $38.0M (Q1 2026) from $34.8M (Q1 2025).
- Repurchased 3.95M shares for $4.8M in Q1 2026 under the stock repurchase program.
- Net cash used in operating activities improved to $(19.3)M from $(34.6)M.
- Company is appealing a $246M foreign tax assessment for 2014-2020.
Price Impact
More from OPK